Publications by authors named "Elizabeth Buck"

Claim this Profile
S
Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain.
Injin Bang, Takamitsu Hattori, Nadia Leloup, Alexis Corrado, Atekana Nyamaa, Elizabeth Buck

Nat Chem Biol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Service user involvement in mental health service commissioning, development and delivery: A systematic review of service level outcomes.
Naseeb Ezaydi, Elena Sheldon, Alex Kenny, Elizabeth Taylor Buck, Scott Weich

Health Expect· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects.
Noboru Ishiyama, Matthew O'Connor, Andrei Salomatov, Darlene Romashko, Shalabh Thakur, Elizabeth Buck

Cancer Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Old dog, new tricks: extracellular domain arginine methylation regulates EGFR function.
David M Epstein, Elizabeth Buck

J Clin Invest· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives.
Meizhong Jin, Elizabeth Buck, Mark J Mulvihill

Oncol Rev· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.
Meizhong Jin, Jing Wang, Elizabeth Buck, Mark J Mulvihill

Future Med Chem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Hui Zhao, Vidhi Desai, Jian Wang, David M Epstein, Mark Miglarese, Elizabeth Buck

Mol Cancer Ther· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Emily M Fox, Todd W Miller, Justin M Balko, Maria G Kuba, Violeta Sánchez, Elizabeth Buck

Cancer Res· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pursuit of personalized anticancer therapy: leveraging collaboration between academia and the biotech/pharmaceutical industry.
Elizabeth Buck, Mark Mulvihill, Kenneth K Iwata

Mt Sinai J Med· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
Elizabeth Buck, Mark Mulvihill

Expert Opin Investig Drugs· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR.
Meizhong Jin, Prafulla C Gokhale, Andy Cooke, Kenneth Foreman, Elizabeth Buck

ACS Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
Elizabeth Buck, Prafulla C Gokhale, Susan Koujak, Eric Brown, Alexandra Eyzaguirre

Mol Cancer Ther· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A community-wide academic-service partnership to expand faculty and student capacity.
Teri A Murray, Anne Schappe, Dale E Kreienkamp, Vanessa Loyd, Elizabeth A Buck

J Nurs Educ· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.
Mark J Mulvihill, Andrew Cooke, Maryland Rosenfeld-Franklin, Elizabeth Buck, Ken Foreman

Future Med Chem· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
Elizabeth Buck, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, Stuart Thomson, Mark Mulvihill

Cancer Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.
Sharon Barr, Stuart Thomson, Elizabeth Buck, Suzanne Russo, Filippo Petti

Clin Exp Metastasis· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Qun-sheng Ji, Mark J Mulvihill, Maryland Rosenfeld-Franklin, Andrew Cooke, Lixin Feng, Elizabeth Buck

Mol Cancer Ther· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.
Elizabeth Buck, Alexandra Eyzaguirre, Sharon Barr, Stuart Thompson, Regina Sennello

Mol Cancer Ther· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Elizabeth Buck, Alexandra Eyzaguirre, Eric Brown, Filippo Petti, Siobhan McCormack

Mol Cancer Ther· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Elizabeth Buck, Alexandra Eyzaguirre, John D Haley, Neil W Gibson, Pablo Cagnoni

Mol Cancer Ther· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
Stuart Thomson, Elizabeth Buck, Filippo Petti, Graeme Griffin, Eric Brown

Cancer Res· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor.
Elizabeth Buck, Henry Bourne, James A Wells

J Biol Chem· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor.
Elizabeth Buck, James A Wells

Proc Natl Acad Sci U S A· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical synthesis of a potent hepatitis C virus RNA replication inhibitor.
Matthew M Bio, Feng Xu, Marjorie Waters, J Michael Williams, Kimberly A Savary, Elizabeth Buck

J Org Chem· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Organization and functions of interacting domains for signaling by protein-protein interactions.
Elizabeth Buck, Ravi Iyengar

Sci STKE· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis